The Cancer Institute Hospital of JFCR

Koto, Tokyo 135-8550

5 studies enrolling now · 8 studies all time

What they study most

Advanced Solid Tumors, Breast Cancer, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Colorectal Carcinoma, Gastric Cancer, Gastroesophageal Junction Cancer, Head and Neck Squamous Cell Carcinomas, Melanoma, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer

Studies at this site

• MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) — Recruiting now
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer — Recruiting now
• This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. — Recruiting now
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% — Recruiting now
• A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer — Recruiting now
• A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) — Running, not enrolling
• PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors — Stopped early
• A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors — Stopped early